171 Oyster Point Blvd
About Tenaya Therapeutics
Tenaya Therapeutics Inc. will build on discoveries in cardiovascular disease research made at the Gladstone Institutes, concentrating on regenerative medicine and drug discovery for heart failure. The new company combines Gladstone’s basic science expertise with the resources and translational know-how of the biotechnology industry.
September 19, 2016
Founders: Deepak Srivastava, Bruce Conklin, Benoit Bruneau and Saptarsi Haldar
9 articles about Tenaya Therapeutics
Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that it will present new preclinical data at the virtual 28th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), October 19 - 22, 2021.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today reported business and program updates and second quarter 2021 financial results.
The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange.
Tenaya Therapeutics to Present Preclinical Data at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
Tenaya Therapeutics, Inc., a company with a mission to discover, develop, and deliver potentially curative therapies that target the underlying causes of heart disease, today announced that it will present preclinical data from four studies as posters at the 23 rd Annual Meeting of the American Society of Gene & Cell T
Proceeds advance heart disease projects from three product platforms toward the clinic
Tenaya Therapeutics Strengthens Leadership Team with Appointment of Two Biopharmaceutical Industry Veterans
Tenaya Therapeutics, a biopharmaceutical company focused on developing potentially curative treatments for heart disease, today announced that it has strengthened its leadership team with the appointment of Whittemore Tingley, M.D., Ph.D., as Chief Medical Officer, and Kee-Hong Kim, Ph.D., as Senior Vice President of Manufacturing and Technical Operations.
Tenaya Therapeutics is a preclinical-stage biotechnology company focused on discovery and development of novel therapies for heart failure
Dr. Hoey is a biopharmaceutical executive with over two decades of experience in the industry.